icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
eNrVWN9v2jAQfueviPJOXNiAdgpUG2s3pFZltGjTXionOcCpsVP/oHR//RxCNzo5amtqaX2M7Xx3vvv83dnx8XpJgxUISTjrh63oIAyApTwjbN4Pp1enzcPweNCIc7zCO8vMuqjdDoOUYin7YTkbJYCZjH6cn30G8z+IcNAIYp7kkKpH67QiNPqK5eIcF+WaIF5xkgVLUAue9cNCq81oEEsljBeDOy5uZIFTiNF2ZHc2v36/Ox6jEuwZqFqCOMNsbgUF5oSZaiGAqSFWMOfivsbfd07YRE5Aci1SGGO1GAu+IhlkVhMzTCU4GZndZZcgVhRUacQKjvJ0KZ3AcY7XE7gd2Z3+aGaHaq2aB81Wr9U77B11O51ep+VkSuyEyp4FswmUXhtL3Xa3jYChXCJKEkSWeA7yjGMT3HIsx5Rws5QLeFiScK4MDC6amUm0IksoSHoDonYiyqVjysdcKEw9JZvI4WO+erIj4PZJUmVEFhTfm0gVrqHCAptpEEZV/G2k3MGVMDpHTcz+wWeaUvRCr6dbFfLkcSlyQ66ZqhGj04lrIIacKVjXZ9RNP9V6y0UC8vVgf3Fmrx1jnVCSuiql0TINUk0no3qhfAMa8wlLmAp/IvOdsIzfydcXr12yePK+2OivFbQQWeu6fXTYbXU6zmfzp2FmTT080YIXgIysEbmPWo3YjO+rU4bsdqgHqv/vLN80ezzFFGravaajEhp6P3Sn3g6Qv8NZTVhBv5xcubLumwZxf7n5tEKTrP+HL25lwkftMRyvdfzlJ6YSDi8XAS3sgrRQqpAfEFpg2ZTYRCiaibdSg3a6CX83Gy8tS9XCVTruyfWkKtDPT7rrwX2qodm3Sd/+v70MWG0ooWGPPFQa702JRyevL+5/O3Rvbo8fiZE/M5tuGivCma92TCdWxP3KickrOxVGHC5mM1LzylTLyxhVL1yDRozK161B4zfPg2cJ
jBeDXuK3FV8wHkX7